Overview

Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC Chemotherapy

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the clinical response rate of neoadjuvant chemotherapy with gemcitabine and cisplatin in patients with operable NSCLC
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Gemcitabine
Criteria
Inclusion Criteria:

- histologic or cytologic diagnosis of operable non-small cell lung cancer (IB-IIIA)

- no prior chemotherapy

- WHO criteria for disease status assessment

Exclusion Criteria:

- Concurrent administration of any other tumor therapy

- pregnant or breast feeding

- serious concomitant disorders